Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of the Effect of Carbamazepine on the Pharmacokinetics of RO4917523 in Healthy Volunteers
- First Posted Date
- 2012-06-27
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 16
- Registration Number
- NCT01629368
ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment
Phase 2
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2012-06-26
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 110
- Registration Number
- NCT01628094
A Study of The Effects of Multiple Doses of Ketoconazole on Single Dose Pharmacokinetics of RO4602522 in Healthy Male Volunteers
- First Posted Date
- 2012-06-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 34
- Registration Number
- NCT01625806
A Single-Ascending-Dose Study of RO5469754 in Healthy Volunteers
- First Posted Date
- 2012-06-15
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 36
- Registration Number
- NCT01620931
An Observational Study of Avastin (Bevacizumab) in Patients With Glioblastoma Multiforme in First or Second Relapse
Completed
- Conditions
- Glioblastoma Multiforme
- First Posted Date
- 2012-06-13
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT01618747
A Study of Tocilizumab in Participants With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Non-Biological Disease-modifying Anti-rheumatic Drugs (DMARDs)
- First Posted Date
- 2012-06-12
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT01617005
A Study to Compare the Bioavailability of Copegus and Vilona® in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2012-06-08
- Last Posted Date
- 2016-11-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT01615393
An Observational Study of RoActemra/Actemra (Tocilizumab) in Rheumatoid Arthritis Patients
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2012-06-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 60
- Registration Number
- NCT01615419
A Study of Aleglitazar in Combination With Oral Contraceptive Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2012-06-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT01615354
A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With Tocilizumab (RoActemra/Actemra)
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Other: No intervention
- First Posted Date
- 2012-06-07
- Last Posted Date
- 2016-10-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 200
- Registration Number
- NCT01613378
© Copyright 2025. All Rights Reserved by MedPath